Ivemend (Fosaprepitant)

Ivemend, an NK1 receptor antagonist, is used in the antiemetic pathway to control chemotherapy‑induced nausea and vomiting.

• Acute chemotherapy‑induced nausea and vomiting (CINV): prevents nausea and vomiting occurring within the first 24 hours after chemotherapy.
• Delayed chemotherapy‑induced nausea and vomiting: reduces symptoms that arise after 24 hours and can last several days.
• Highly emetogenic chemotherapy regimens: enhances overall antiemetic control when combined with 5‑HT₃ antagonists and dexamethasone.

• Fosaprepitant selectively blocks the neurokinin‑1 (NK1) receptor, inhibiting the binding of substance P, a neuropeptide that mediates emetic signaling in the central nervous system. By preventing this interaction, the drug interrupts the vomiting reflex pathway triggered by chemotherapy, thereby reducing both acute and delayed nausea and vomiting.

Fosaprepitant may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Headache: mild to moderate pain in the head.
• Fatigue: feeling of tiredness or lack of energy.
• Injection site reactions: pain, erythema, or swelling at the infusion site.
• Constipation: reduced bowel movements or hard stools.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction with respiratory distress.
• Severe hypotension: marked drop in blood pressure requiring intervention.
• Stevens‑Johnson syndrome: serious skin and mucous membrane disorder.
• Hepatic enzyme elevation: significant increase in liver function tests.

When using Ivemend, several precautions should be observed to ensure patient safety.

• Assess hypersensitivity: review patient history for known allergy to NK1 antagonists or fosaprepitant components.
• Monitor infusion reactions: observe for signs of rash, fever, or respiratory changes during administration.
• Adjust for hepatic impairment: consider dose modification or increased monitoring in patients with moderate to severe liver dysfunction.
• Avoid concomitant use with strong CYP3A4 inhibitors: these may increase fosaprepitant exposure and risk of toxicity.
• Review QT‑prolonging medications: evaluate cardiac risk when combined with other agents that affect cardiac repolarization.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Fosaprepitant can interact with several drug classes; awareness of these interactions helps optimize therapy.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may markedly increase fosaprepitant plasma levels.
• Strong CYP3A4 inducers (e.g., rifampin, phenytoin): may substantially reduce drug exposure and efficacy.
• Concurrent NK1 antagonists: additive pharmacodynamic effects increase risk of adverse reactions.

Moderate Interactions (Monitor Closely)

• Moderate CYP3A4 inhibitors (e.g., erythromycin, fluconazole): may modestly raise fosaprepitant concentrations.
• QT‑prolonging agents (e.g., ondansetron, droperidol): combined use may enhance risk of cardiac arrhythmias.
• Warfarin: potential alteration of anticoagulant effect; monitor INR closely.